Abstract
Tyra Biosciences has raised $50 million in series A financing to develop small-molecule drugs for treatment-resistant cancers. The Carlsbad, California–based start-up is focused on cancers that have acquired resistance to tyrosine kinase inhibitors, a class of more than 40 approved drugs. Tyra was founded in 2018 by Daniel Bensen, former head of immunology and protein chemistry at Cidara Therapeutics, and Todd Harris, founder and former CEO of Sienna Labs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
